Company: BWNB
Filing Date: 2025-06-10
Form Type: 424B5
Source: 0001104659-25-058204
Chunk: 15

Company: Babcock & Wilcox Enterprises, Inc.
Filing Date: 2025-06-10
Form: 424B5
Chunk 15
---
 even if the offer may be considered beneficial by some shareholders and
could delay or prevent an acquisition that our board of directors determines is not in the best interests of the Company and our shareholders.

| S-7 |

<div align='center'>USE OF PROCEEDS</div>

In accordance with the terms
of the Sale Agreement, under this prospectus supplement and the accompanying prospectus, we may issue and sell up to $50,000,000 of shares
of our Common Stock from time to time through the Agents. The amount of net proceeds we will receive from this offering, if any, will
depend upon the actual number of shares of Common Stock sold and the market price at which such shares are sold. Further, because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and
net proceeds to us, if any, are not determinable at this time.

On January 18, 2024, the
Company entered into a credit agreement (as amended, restated or otherwise modified from time to time, the “Credit Agreement”)
with certain of its subsidiaries as guarantors, the lenders party thereto from time to time and Axos Bank (“Axos”) as administrative
agent. Under the Credit Agreement, the net cash proceeds from any equity issuance must first be applied to prepay the loans outstanding
under the Credit Agreement; however, we may reborrow any amounts prepaid, subject to customary conditions.

We intend to use the net
cash proceeds of this offering to prepay amounts outstanding under our Credit Agreement and subsequently reborrow such amounts under our
Credit Agreement, and intend to use any such reborrowed amounts for working capital and general corporate purposes. Pending such use,
we may invest the net proceeds in short-term interest-bearing accounts, securities or similar investments. The precise amount and timing
of the application of the net proceeds will depend upon our capital requirements and the availability of other funds.

The Credit Agreement provides
for an up to $150.0 million asset-based revolving credit facility (with availability subject to a borrowing base calculation) (the “Credit
Facility”), including a $90.0 million letter of credit sublimit. Our obligations under the Credit Agreement are guaranteed by certain
of our domestic and foreign subsidiaries.

As of June 9, 2025, we had
approximately $119.6 million outstanding under our Credit Agreement. The Credit Agreement has a maturity date of January 18, 2027; provided